CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 4,994 enrolled
Drug / intervention
Blood transfusionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01638416
NCT01638416Phase 3Completed

A Multi-centre Randomised Double Blinded Phase III Trial of the Effect of Standard Issue Red Blood Cell Blood Units on Mortality Compared to Freshest Available Red Blood Cell Units

Australian and New Zealand Intensive Care Research Centre·interventional·Posted Jul 11, 2012·Updated Oct 22, 2020

In Brief

A Phase 3 clinical trial evaluating Blood transfusion for Transfusion and Age of Blood. Completed, enrolled 4,994 participants across 60 sites in 5 countries.

Detailed Summary

In Australia, blood for transfusion has a "use by" date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage. During the last decade, it has been reported that blood transfusion in patients admitted to intensive care was associated with an independent increase of mortality. Some research suggests that transfusion of fresher blood might help patients in the intensive care unit to reach a better recovery. This project will test whether patients who receive 'fresher' blood do better than patients who receive 'standard issue' blood.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Finland, Ireland, New Zealand, Saudi Arabia

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 11, 2012
Enrollment StartOct 1, 2012
Primary CompletionApr 1, 2017
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 14.0 years ago

Interventions

Blood transfusionother

Blood transfusion in ICU patients aged 18 and over.